Share This Page
Suppliers and packagers for KLOXXADO
✉ Email this page to a colleague
KLOXXADO
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Hikma | KLOXXADO | naloxone hydrochloride | SPRAY;NASAL | 212045 | NDA | Hikma Specialty USA Inc. | 59467-679-01 | .1 mL in 1 VIAL, SINGLE-DOSE (59467-679-01) | 2021-08-03 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Kloxxado
Introduction
Kloxxado (generic name: naloxone hydrochloride) is a critical pharmaceutical agent used primarily to counteract opioid overdoses. Its significance has surged amidst ongoing opioid epidemics worldwide, prompting a comprehensive analysis of its supply chain. Understanding the landscape of Kloxxado suppliers is essential for healthcare providers, policymakers, and pharmaceutical businesses aiming to ensure consistent access, compliance, and affordability. This article examines the key suppliers, manufacturing landscape, market dynamics, regulatory frameworks, and future outlooks associated with Kloxxado.
Overview of Kloxxado and Its Market
Kloxxado is marketed as a nasal spray formulation of naloxone, designed for rapid administration during opioid overdoses. It is a product of Adapt Pharma, a subsidiary of Johnson & Johnson (J&J), which gained prominence for its user-friendly delivery mechanism, line with public health efforts to expand overdose reversal access [1]. The drug has been classified as a 505(b)(2) FDA-approved product, allowing for streamlined approvals and fostering a competitive generic market.
The rising demand for naloxone-based overdose reversal agents, driven by the opioid crisis, has created a substantial and expanding market. As of 2023, multiple manufacturers have endeavored to produce both brand-name and generic versions, including Kloxxado. However, the market remains highly concentrated among a few key suppliers.
Primary Suppliers and Manufacturing Landscape
1. Johnson & Johnson (through Adapt Pharma)
Originally, Kloxxado was developed and marketed by Adapt Pharma, acquired by Johnson & Johnson in 2019. J&J's extensive manufacturing capabilities have made it a dominant supplier in the naloxone nasal spray segment. The company operates manufacturing facilities compliant with Good Manufacturing Practices (GMP), ensuring high-quality standards.
J&J’s global reach allows for widespread distribution and availability to healthcare providers and government programs. Despite its position, J&J faces competitive pressures as generic manufacturers enter the space.
2. Teva Pharmaceuticals
Teva is one of the leading generic pharmaceutical manufacturers globally. It produces naloxone nasal spray products approved as generics of Kloxxado or comparable formulations. Teva’s extensive manufacturing network and existing infrastructure facilitate large-scale production, making it a significant supplier.
3. Adamis Pharmaceuticals
A specialty biotech firm, Adamis develops naloxone formulations, including nasal sprays. The company has sought to secure FDA approval for its product lines, which could serve as additional suppliers in the near future.
4. Hikma Pharmaceuticals and Others
Hikma Pharmaceuticals, a global pharma company, and several regional manufacturers have entered the naloxone nasal spray market, primarily targeting local healthcare markets and government agencies.
5. Emerging Generic Manufacturers
Recent years have seen an influx of smaller manufacturers seeking FDA approval for generic naloxone nasal sprays. Companies such as Mylan (now part of Viatris), Amphastar Pharmaceuticals, and others are evaluating or have launched competing formulations, aiming to diversify the supply chain.
Regulatory and Patent Factors Influencing Supply
Kloxxado's original patent exclusivity has expired or is nearing expiration, opening pathways for generics. The FDA’s approval process for generic nasal sprays relies on demonstrating bioequivalence, which many companies have achieved, increasing supply diversity. Moreover, the U.S. government's policies promoting naloxone distribution—such as increased funding and standing orders—motivate manufacturers to scale production.
It is also notable that certain formulations, including nasal sprays, may benefit from orphan drug designations or other incentives that influence manufacturing and supply decisions.
Market Dynamics and Supply Challenges
1. Supply Chain Constraints
Global supply chains for active pharmaceutical ingredients (APIs) and specialized packaging components are susceptible to disruption, impacting product availability. The COVID-19 pandemic highlighted vulnerabilities in raw material procurement, affecting naloxone supply volumes.
2. Demand and Stockpiling
Healthcare systems and harm reduction organizations have increased stockpiling of naloxone products, particularly Kloxxado, to address overdose crises. This surge has occasionally strained manufacturing capacities, prompting calls for expanded production.
3. Price and Accessibility
Pricing strategies vary among manufacturers, with competitive generic options helping reduce costs. However, high demand coupled with supply limitations in certain regions pose access challenges, especially in underserved communities.
4. Regulatory Approval Rates
The pace at which new manufacturers obtain FDA approval impacts market diversity. Faster approval facilitates increased supply but may also raise concerns about quality and safety standards enforcement.
Future Outlook for Kloxxado Suppliers
The growing emphasis on overdose prevention is likely to sustain high demand for naloxone nasal sprays. Several key trends are shaping the supplier landscape:
-
Expansion of Generic Production: As patent protections expire, more manufacturers will enter the market, increasing supply options.
-
Innovation in Formulation: Development of long-acting formulations and alternative delivery mechanisms could diversify supply channels.
-
Policy and Funding Influence: Government programs providing subsidies and mandates for naloxone distribution will incentivize production expansion.
-
Global Market Development: Countries outside the U.S. are increasingly adopting naloxone, creating opportunities for international suppliers.
Strategic Considerations for Stakeholders
Healthcare providers and distributors should monitor regulatory approvals, manufacturing capacity expansions, and market entries by emerging suppliers. Policymakers need to support scalable manufacturing and streamline approval pathways to ensure steady access. For pharmaceutical companies, investing in capacity expansion and technological innovation in naloxone delivery systems represents a critical growth avenue.
Key Takeaways
- Johnson & Johnson’s Adapt Pharma remains a primary supplier of Kloxxado, supported by strong manufacturing infrastructure.
- Several generic manufacturers, including Teva, Adamis, and Hikma, contribute to the diversified supply landscape.
- Patent expirations and FDA approvals have opened the market to increased competition, improving access but also requiring vigilant supply chain management.
- Manufacturing and supply are vulnerable to global disruptions; proactive capacity planning is essential.
- Public health policies and funding significantly influence supply stability and market growth.
FAQs
Q1: Who are the main manufacturers supplying Kloxxado or its equivalent?
A1: Johnson & Johnson (via Adapt Pharma), Teva Pharmaceuticals, Adamis Pharmaceuticals, Hikma Pharmaceuticals, and other generic manufacturers are key suppliers.
Q2: How does patent law impact the supply of naloxone nasal sprays like Kloxxado?
A2: Patent expirations enable generic manufacturers to produce bioequivalent formulations, increasing supply options and market competition.
Q3: Are there significant regional differences in Kloxxado supply?
A3: Yes, supply is often concentrated in the U.S. and developed markets, with regional regulations and manufacturing capacities affecting availability elsewhere.
Q4: What are the main challenges faced by Kloxxado suppliers?
A4: Supply chain disruptions, rising demand, regulatory hurdles, and pricing pressures are primary challenges impacting manufacturing and distribution.
Q5: What is the future outlook for Kloxxado supply?
A5: The market is expected to expand with more generic options and innovative formulations, supported by policy initiatives and increased global adoption.
Sources
[1] Johnson & Johnson. “Johnson & Johnson Acquires Adapt Pharma and Its FDA-Approved Naloxone Nasal Spray.” 2019.
More… ↓
